Background Pertussis has substantially increased in Quebec, Canada, since 1990. We
estimated pertussis vaccine effectiveness and vaccine coverage in child-care centers and …

Objective. Currently, 4 diphtheria-tetanus-acellular pertussis (DTaP) vaccines are licensed
for pediatric use in the United States, and 2 are commercially available. Although a single …

Background. In 1992–1993, a randomized, double-blind, placebo-controlled clinical trial of
two 3-component acellular pertussis vaccines was started in 4 of Italy's 20 regions. During …

In a double-blind, placebo-controlled efficacy trial of a monocomponent pertussis toxoid
vaccine, 3450 infants were randomly assigned to vaccination with diphtheria-tetanus toxoids …

Importance Infants younger than 1 year have the highest burden of pertussis morbidity and
mortality. In 2011, the US introduced tetanus toxoid, reduced diphtheria toxoid, and acellular …

Sustained high incidence of pertussis, particularly amongst unvaccinated infants, is of
concern. Inclusion of pertussis vaccination with tetanus and low dose diphtheria (Td) …

A subanalysis of a recent cohort efficacy trial of a pertussis vaccine was performed to
determine its efficacy against cough illnesses due to Bordetella parapertussis infections …

This is the first study in children from the United States that evaluates the immunogenicity of
and adverse reactions to the Connaught/Biken two-component acellular pertussis vaccine …

Booster vaccination with a reduced-antigen-content dTpa, pediatric DTPa or adult Td
vaccine in DTPa-primed children aged 4-6 years was evaluated. Immunogenicity and CMI …

Background The acellular pertussis vaccine has been used in the Norwegian national
immunisation program since 1998. Following an increase in pertussis incidence in all age …